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Abstract 
Aim: The objective is to contribute with real world evidenced economic forecasts of diabetes at-
tributable costs in 2025 and 2040 differentiated according to patients’ morbidity status which is a 
novel approach within forecasting. Methods: Method of forecasting is based on an annual calendar 
year prediction of diabetes attributable costs by using the BOX-model, an established and tested 
epidemiological transition-state model. The study population includes all Danish diabetes patients 
presented in 2011 (N= 318,729) according to the Danish National Diabetes Register. Forecasting is 
based on individual patient data from 2000 to 2011 for incidence, mortality, patterns of morbidity 
and complication rates combined with demographic population projections from Statistics Den-
mark. The 2011 estimation of diabetes attributable costs were applied to the epidemiological 
framework. Forecasting was performed for three different epidemiological scenarios.Results: Our 
three epidemiological scenarios indicate that within the shorter time span increases in the preva-
lent population are difficult to change primarily due to the already achieved historic improve-
ments in diabetes mortality and morbidity. These will approximately double societal costs of di-
abetes in the next 10 years,assuming current trends in morbidity and mortality are main-
tained.The resulting diabetes population will incur three times current costs in 2040.A 20% re-
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duction in cost per PYRS shows how the relative distribution of patients with complications is ex-
pected to change over time with patients living better with their disease and hence incur a lower 
demand for health and nursing care services. 
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1. Introduction 
Chronic diseases are one of this century’s greatest threats towards public health with almost epidemic preva-
lence increases globally and expectations of significant increases in the future [1]. Diabetes Mellitus is, with 
around 350 million people globally suffering from this disease [2] [3], one of the most burdensome chronic dis-
eases associated with major disability, reduced quality of life and shortened length of life [2] [4]. 
Various factors are expected to cause future increase in the prevalence of diabetes: demographic changes[5], 
sedentary life styles and obesity [6]-[8], improved survival [9] [10] epidemiology [11], screening efforts [12] 
and new morbidity patterns implying that diabetes is increasingly seen in younger ages [13] [14]. Management 
of the increasing diabetes population implies, among others, an economic challenge, which societies must face, 
as diabetes patients require increased health care, pharmaceuticals and nursing services for their remaining life-
time[4] [15] [16]. Long term models can identify where a society may be heading, providing policy makers with 
a foundation on which decisions concerning future strategic prioritization can be grounded [17]. 
Forecasts of the burden of diabetes exist in great numbers in the literature, see for example, King et al. 1998 
[18],Bagust et al. 2002 [19], Huang et al. 2009 [20], Mainous et al. 2007 [21] or Tunceli et al. 2009 [22]. Our 
forecasting model (the BOX-model) is an established and tested epidemiological disease model, which has 
proven its global applicability for different diseases with largely accurate predictions showing only nonessential 
deviations[9] [23] [24]. The BOX-model is simple and intuitive, based on epidemiological drivers observed over 
more than a decade and economic cost estimates for 2011 calculated on the individual level from national registers. 
Based on a comprehensive epidemiological framework, this study forecasts diabetes attributable costs in 
Denmark for the period 2012-2040 according to sectors and patient’s morbidity status. Denmark has optimal 
conditions due to data availability, coverage of the diabetes population and richness of information in national 
registers [25]. In addition, Denmark is a typical European country in terms of treatment availability and popula-
tion structure. The study was part of a large-scale register based on observational investigation, the Diabetes 
Impact Study 2013 [26], which investigated epidemiological, health economic and socioeconomic aspects of 
diabetes in Denmark [11] [16] [27]. 
2. Method 
Estimating the size of future costs attributable to diabetes, the epidemiological dynamics underlying the preva-
lence of diabetes must be taken into account. Each year, new patients are diagnosed, patients develop complica-
tions and yet other patients will die. These dynamic structures are appreciated in the forecasts through the un-
derlying epidemiological framework, presented in the BOX-model. 
2.1. The BOX-Model 
To model the future prevalent diabetes population, this study uses a simple multi-state transition model, the 
BOX-model, a flexible epidemiological framework, based on individual data from the entire Danish diabetes 
population. The BOX-model, (Figure 1) has been validated [9] and thoroughly described elsewhere [11]. 
In the BOX-model, an individual is either non-diabetic (population at risk) or belongs to one of the diabetic 
complication groups: CG0, no complications; CG1, minor complications or CG2, major complications. ICD-codes 
defined for each complication group is given in the supplementary material (A). Health states in the model are mu-
tually exclusive and collectively exhaustive meaning that each patient can only be in one state in a cycle and must 
be in a state in each cycle. Cycles are measured in calendar years [28]. Irreversibility is assumed and,therefore, 
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Figure 1. The BOX-model. 
 
patients can only move forward in the model. Influx (new incident cases) and outflux (mortality) as well as in-
flux to each of the complication groups were accounted for on an annual basis. Forecasting is based on patient 
groups defined by gender and age at diagnosis in 25 year age intervals. 
2.2. Study Population 
The study population was based on the entire diabetes population in Denmark in 2011, adjusted according to 
shortcomings in the Danish National Diabetes Register, specified elsewhere [29], N = 318,729. Person years 
(PYRS), defined as 365 person days, N=297,378 in 2011 were applied. The study population was compared to 
the Danish diabetes-free population (N= 5,261,714) and to a matched (gender, age and municipality of residence) 
control population from the diabetes-free population (N= 1,462,872). 
2.3. Data Sources for Epidemiological Forecasting 
The epidemiological forecasting was based on observed individual patient level data on the entire Danish di-
abetes population from 1997 through 2011 through Danish national registers [11]. Transition probabilities be-
tween states were extrapolated from the observed data resulting in a prevalence (PYRS) in each health state in 
every calendar year. This means that the exact number of projected PYRS in 2011 deviates from the observed 
number, however the deviation is <1%. To facilitate comparison with earlier studies [11] [16] [27], we state the 
observed numbers from 2011. PYRS were stratified by gender and age at diagnosis in 25 year age intervals. The 
diabetes-free population, and hence population time at risk of developing diabetes, for each calendar year until 
2040 was calculated from demographic population projections from Statistics Denmark based on recent trends 
for vital demographic events: birth rate, death rate, immigration, emigration and naturalization, converging to-
wards a long time perspective level based on annual forecasts [29]. This epidemiological forecasting make up 
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the framework on which 2011 cost estimates are added. 
2.4. Data Sources for Economic Forecasting 
Age at diagnosis, gender and complication status, among other characteristics, influence on patients costs [16]. 
Estimates for diabetes attributable costs according to these characteristics were calculated and applied to the ep-
idemiological model.Diabetes attributable costs for 2011 were calculated as the difference between total costs of 
a person with diabetes and the expected total costs given the annual resource consumption of the control popula-
tion stratified according to gender and five-year age intervals. The included cost components are listed in Table 
1 along with measurement of cost components and described in more detail elsewhere [16]. 
 
Table 1. Cost components, cost units and method of calculation. 
Cost component Cost unit and method of calculation 
Inpatient and outpatient services delivered 
in Danish hospitals registered in DNPaR 
Diagnosis Related Grouping system tariffs, year 2012 [30].The 
DRG tariff system is developed for administrative purposeand 
based on rough average costs across hospitals for specific 
diagnostic groups. Excludes interest and depreciation of buildings 
and equipment while other overhead costs are included. 
Primary care services delivered by general 
practitioners andprivately practicing specialists 
such as: dentists, physiotherapists, chiropractors 
and chiropodists who are registered in DNHSR 
Reimbursement fees between the National Health Insurance scheme 
and private practicing physicians are used as cost units. General 
practitioners are compensated by regions through a combination of 
per capita fee (app.30% of total) and fee for service (app. 70%) [31]. 
To reflect this payment scheme in the unit cost, 43.8% of the fee for 
service in general practice was added on top. Overhead costs covered 
by capitation fee were, hence not distributed across numbers of visits, 
as would have been most appropriate, but by resource burden. 
Prescribed pharmaceuticals dispensed by 
Danish pharmacies and registered in DNPrR 
(Pharmaceuticals consumed in hospitals are 
included in DRG-tariffs. Over-the-counter 
drugs are not included in the statements) 
Total Sales Price (TSP) includes patient Out of Pocket Payments (OPP), 
since costs of prescribed pharmaceuticals are shared between the patient 
and the primary health care sector by a copayment scheme, where patients 
are reimbursed according to their need. These costs were aggregated, since 
total costs are measured regardless of who pays. While pharmaceutical 
consumption includes value added tax (VAT), Danish health care services 
are exempted from VAT. Given that VAT is 25% in Denmark, 20% of 
pharmaceutical consumption was subtracted to get comparable net costs. 
Costs of living in a nursing home/sheltered  
accommodation 
Based on individually registered address in SD 
Unit cost was calculated as total annual costs of running these facilities 
divided by the number of inhabitants, 51,486 DKK (exclusive of capital 
costs) per person living in nursing homes per year. Hereto was added 
average number of hours of nursing received by persons living at nursing 
homes or sheltered accommodation calculated by SD equal to 18.6 hours 
per week per person or 565,283 DKK applying a unit cost of 588 DKK 
per hour. In total 616,769 DKK per person per year. The cost unit included 
overhead and administration but not capital costs. 
Referred monthly personal nursing and 
practical care in own home per year 
based on individual registrations in SD 
Registrations on volume of services were, incomplete whereas whereas number of 
individuals receiving care appeared rather completely registered. Therefore, 
national volume estimates from SD were applied together with the number 
of PwD receiving care compared to the expected number given the observed 
frequency among the diabetes-free population, in gender and age strata, to 
estimate the amount of nursing services received attributable to diabetes. 
Average number of hours of nursing received by persons living in their own 
home was estimated to be 3.6 hours. The unit cost was defined as average costs 
for one hour of nursing delivered in the given year (calculated as the total costs 
for nursing divided by number of hours of care delivered in the year),based 
on data published by SD, equal to 588 DKK per hour. 
Home nurse visits per year based on 
individual registrations in SD 
Number of visits by home nurse appeared rather completely registered on an 
individual basis. Unit cost was calculated as average costs for home nurses 
per inhabitant times the Danish population divided by the total number of 
services,based on data published by SD.One service is estimated to be 456 DKK. 
C. Sortsøet al. 
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Continued 
Productivity loss based on data from SD Lost productivity attributable to diabetes were accounted for through an estimation 
of 1) Annual mean gross income difference from expected income given educational 
level, gender and age; 2) Premature mortality; 3) Abseentism. 
1) Sum of absolute difference in annual gross income between PwD and controls 
aggregated for patients older than 14 years and younger than 69 in strata by gender, 
age in 5 year intervals and four educational levels (1: < 11 years of education; 
2: < 16years; 3: < 18 years and 4: 18+ years) 
2) Sum of annual foregone income due to lost years of productivity in cases of 
premature death for: 2a) 2011 and 2b) productivity loss in 2011 due to deaths 
attributable to diabetes occurred prior to 2011. Since data is not available on 
deaths attributable to diabetes for the past 45 years, we used attributable deaths 
in 2011 and the production loss that will incur in the future until the age of 69 
to mirror the foregone production well knowing that this method builds on the 
simplified assumption that diabetes mortality and labour market patterns the past 
decades have not changed. For persons between the age of 15 and 69, number 
of relative deaths by gender and 10-year age group was compared between PwD 
and controls and the difference is assumed to represent deaths attributable to 
diabetes. Number of attributable deaths in each strata was multiplied with the 
average wage of a diabetes-free person in that strata. 2a) Strata were aggregated 
and the sum was divided by 2 assuming deaths are equally spread over the entire 
calendar year. 2b) Mid age in each age-interval was used as proxy and then 
number of years until the age of 69 was calculated and multiplied with number of 
attributable deaths in the given strata again multiplied with the average annual 
gross income among a diabetes-free person in that strata. 
3) Number of days of absence due to diabetes is calculated based on literature 
estimates of 3 extra days a year. Daily wage is calculated as the mean annual 
income among PwD divided by 200 working days. 
SMBG costs (meters and sticks) 
and insulin pumps 
Cost of SMBG (for the 22% of PwD using insulin) was estimated on the basis 
of a study of SMBG costs in Canada to annually 860 US$ equivalent to 6175 
DKK (2011 prices) [32]. 
According to the Danish Ministry of Health and the Danish Diabetes Association 
[33] pumps were used by approximately 2100 PwD and the annual cost ranged 
from 22,000 to 39,000 DKK in 2010. For 2011,we have applied a conservative 
cost estimate of 22000 DKK for80% of all T1 children (0-14 year) and for 5% 
of the rest of the T1 population in total amounting to 2450 PwD. Censors are not 
included in this cost and would approx. double the annual cost of pumps. 
Appliances (blind assistance, protese crus, 
femur, wheel chairs, sticks) 
Unit costs of blind assistance was calculated on the basis of the MTV report [34]and 
includesassistance outside home, sticks and guide dogs, IT solutions for blind parents, 
blind library appliances and amounted to 99,137 DKK per year (2011 prices). 
The cost cover needs for the 1.1% -1.6% (amounting to approx. 3372 persons) of 
the diabetes population that is considered socially blind [34]. 
The cost of a crus and femur prosthesis was estimated to be respectively 17,000 
and 44,000 DKK per year. In 2011, 1348 (crus) and 768 (femur) persons with 
diabetes lived with an amputation and respectively 75% and 50% of those were 
assumed to have a prosthesis. The rest of the amputated persons are assumed to 
use wheel chairs. 
The cost of wheel chairs was calculated from an average of different chair types 
(ranging from a cost of 2,589 to 34,109 DKK) [35]to an annual average cost of 
2,450 DKK. 25% of diabetes patients (above 45 years) with complications are 
assumed to need a wheel chair. 
Prevention, education and psychological 
assistance 
A total of 4 hours per diabetes patient under 29 years (3%) and all persons 
diagnosed during 2011 (10%) and 1 hour for 50% of the rest of the diabetic 
population was applied as an estimate of the received support in any of the 
following forms (prevention initiatives, educational training or psychological 
assistance, telemedicine etc.) An hourly cost of 588 DKK was applied. 
Patients’ own time to monitor their disease 
and informal care takers support for relatives 
(0-15 years and above 75 years) 
According to an evaluation [36] [37] by diabetes educators, experienced diabetes 
patients controlled by oral agents would use 2 hours a day when asked to follow 
the American Diabetes Association self-care recommendation and elderly and 
handicapped patients would use more. Exercise and diet, required for self-care 
of many chronic conditions, are the most time-consuming tasks. We included 
a conservative estimate of patients’ time (1 hour per week per patient) and 
informal caregivers’ time (8 hours per year per patient) at a cost of 25% of the 
productive value. 
Depreciation  Data on costs of capital depreciation in secondary care and for nursing 
services were included with 20% of secondary care and nursing costs. 
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Given that cost estimates for the year 2011 were originally calculated according to age in five year inter-
vals,these estimates were recalculated to age at diagnosis in 25 year age groups. Due to data limitations, this re-
calculation was not possible for nursing services and additional cost components. Therefore, we applied the 
same cost structure between age and age at diagnosis for these two cost components as found for health care 
costs. Furthermore, we maintained total attributable cost estimates calculated on age groups and applied the es-
timated cost structure between age and age at diagnosis across strata based on these totals. Cost calculations of 
productivity loss due to premature mortality were calculated based on assumptions concerning the mortality rate. 
Hence, the model considers the annual assumed mortality rate and adjusts productivity loss due to premature 
mortality correspondingly. Calculation of depreciation of capital was based on the size of the secondary health 
care sector cost component. All costs were calculated in fixed 2011 values. 
3. Scenarios 
Comparison between three contrasting scenarios was deployed. Each scenario was related to the same base year 
(2011) and outlines a situation specified according to observed epidemiological trends in incidence, mortality 
and complication progression from 1997-2011. The three scenarios represent: 1) continuation of observed epi-
demiological trends under the assumption that these trends will continue as historically observed (core); 2) con-
tinuation of the observed trends regarding mortality and complication rates but a constant rate of incidence as 
observed in 2011, reflecting the assumption that incidence will stabilize and discontinue the increase (interme-
diate); 3) all epidemiological drivers are kept constant on the level observed in 2011 to reflect no further im-
provements in mortality and morbidity among diabetes patients and no further incidence increase (constant). 
Scenarios are presented in Table 2. 
For each scenario, the BOX-model calculates a distribution of PYRS. By adding estimates of diabetes attri-
butable costs specific for gender and age at diagnosis, total diabetes attributable sector costs for every calendar 
year are arrived at. 
 
Table 2. Epidemiological scenarios. 
Scenario Drivers Description 
Core 
Continuation of trends 
Incidence Continuation of 2001-2011 observed 
increasing trend 
Mortality Continuation of 2001-2011 observed 
decreasing trend until X 
Complication rate transitions Continuation of 2001-2011 observed 
trends: reduction in transition from 
CG0 to CG1 and CG2 until X 
Intermediate 
Stagnation in incidence + 
continuation of trends in 
morbidity and mortality 
Incidence Stabile rate as observed in 2011  
Mortality Continuation of 2001-2011 observed 
decreasing trend until X 
Complication rate transitions Continuation of 2001-2011 observed 
trends: reduction in transition from 
CG0 to CG1 and CG2 until X 
Constant 
Continuation of 2011 level 
Incidence Stabile rate as observed in 2011 
Mortality Stabile rate as observed in 2011 
Complication rate transitions Stabile rate as observed in 2011 
4. Economic Potentials 
The cost forecasts mirror the observed cost structure and level in 2011, though it is obvious that the future will 
not hold the same investments and treatment/cost structures as in 2011. A prerequisite for the proposed epidemi-
ological scenarios is, therefore, to capture some structural changes and potential relevant investment cases. On the 
one hand, the continuation of treatment improvements as assumed in scenarios (core and intermediate) cannotbe 
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expected without some future investments in pharmaceuticals and health care. On the other hand, the cost levels 
in health care, nursing and pharmaceuticals will ultimately be decided, by what is politically possible in the 
years to come. Hence, the challenge is to quantify implications hereof for the cost forecasts. To accommodate 
this in our model, we suggested a number of hypotheses representing, on one hand, potentials for freeing of re-
sources if certain efficiency improvements are realized or of a given political or administrative initiative and, on 
the other hand, budget limitation or economic potentials of a given investment. Based on the Core scenario each 
of the hypotheses was estimated under the assumption of everything else held constant. 
Hypotheses, rationale and corresponding model adjustments are described in Table 3 and Table 4. 
 
Table 3. Description of hypotheses, rationale and model adjustment method: economic potential of investments. 
Hypothesis Rationale Model adjustment method 
Economic potential of a given investment   
H1: Increased investments 
in primary care 
Focus on patient self-care initiatives and improved 
health among patients with diabetes can be expected 
to move patients from secondary to primary care. 
5% annual increase in costs per 
PYRS in primary care (200% 
increase in 2040) 
H2: Increased investments 
in pharmaceuticals  
Investments in new and better pharmaceuticals plus a 
more proactive medication of PwD can be expected 
to increase pharmaceutical costs. 
2.5% annual increase in costs 
per PYRS for pharmaceuticals 
H3: Increased investments 
in secondary prevention such 
as telemedicine 
Telemedicine for patients with chronic diseases as 
diabetes are in rapid development [38] [39]. Investments 
in telemedicine have the potential to reduce patients’ need 
for health care services and improve their daily regulation. 
Increased investments in secondary prevention to increase 
self-management can be expected to improve the regulation 
of diabetes patients, who have not yet developed 
complications from their disease. 
2.5% annual increase in cost 
per PYRS for 
—H3a SMBG 
—H3b patient education 
—H3c patients’ own time for 
managing their disease 
 
Table 4. Description of hypotheses, rationale and model adjustment method: potential for freeing of resources of a given in-
itiative. 
Hypothesis Rationale Model adjustment method 
Potential for freeing of 
resourcesof a given political 
oradministrative initiative 
  
H4: Efficiency improvements in 
a) the health care sector 
b) nursing services 
Annual productivity gains are achieved in the Danish 
health care sector/nursing sector. In the period 2003-2011, 
the annual productivity gains in the Danish health care 
sector has been 2.3% and in 2011 alone 5.3% [40]. 
Annual 1% reduction ofcostper 
PYRS for 
H4a—primary andsecondary care 
H4b—all nursingcomponents 
H5: Reduced usage of 
nursing services 
Patients with diabetes live longer and better with their 
diabetesand in comparison with 2006 estimates, the 
2011 cost structureimplies relatively less costs fornursing 
[16]. This can also be aconsequence ofstructural changes 
in the Danish nursing sectorwith reduced services. If these 
developments are continued, theneed for/usage of nursing 
services per PYRS can be expectedto further decrease over 
time. The number of nursing homesand similar housing for 
elderly in 2011 have decreased with62% of the level in 
2005 [41]. 
Annual 2.5% reductionperPYRS 
in all nursingcost components 
H6: Reduced usage of 
secondary care services 
 Annual 2.5% reduction in costs 
per PYRS in secondary care 
H7: Reduced productivity 
loss among patients in CG0 
Improved regulation of diabetes patients who have not yet 
developed complications from their disease. 
If CG0 patients were able to contribute more equal to thediabetes- 
free population on the labour market, productivitylosses due to 
lower income and excess absence could bedecreased. 
Annual 2.5% reduction perPYRS 
in productivity lossdue to difference 
in annualincome and excess absence 
for patients in CG0 
5. Results 
All cost estimates are presented in 2011 EUR based on a conversion rate from DKK to EUR of 7.4647 DKK. 
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5.1. Total Attributable Costs of Diabetes 2011-2040—The Three Scenarios 
We have previously estimated total attributable costs of diabetes to the Danish society in 2011 to be at least 4.27 
billion EUR, corresponding to 14,349 EUR per PYRS [16]. Forecasting estimates of total diabetes attributable 
costs and costs per PYRS for each cost component in the three epidemiological scenarios are presented for the 
years 2025 and 2040 in Table 5. More detailed specification of distribution of costs according to sectors and 
complication groups together with epidemiological indicators are given in supplementary material (B). 
 
Table 5. Prevalence, total attributable costs and cost per PYRS 2011, 2025 and 2040 in three epidemiological scenarios. 
Scenarios  CORE INTERMEDIATE CONSTANT 
Prevalence 2011 2025 2040 2025 2040 2025 2040 
Total 300.769 644.738 1.183.630 564.781 862.623 516.239 660.102 
Comp 0 166.327 372.443 708.091 320.497 504.314 270.745 320.276 
Comp 1 57.415 123.738 219.485 112.333 171.215 106.545 139.486 
Comp 2 77.027 148.557 256.055 131.951 187.094 138.949 200.340 
Costs1.000 EUR 2011 2025 2040 2025 2040 2025 2040 
Health care 725.464 1.431.167 2.455.206 1.286.964 1.842.157 1.315.790 1.850.934 
Pharmaceuticals 149.954 306.039 532.748 274.265 400.288 267.676 359.782 
Nursing 849.716 1.619.462 2.706.185 1.468.785 2.063.159 1.544.347 2.236.536 
Production loss 1.750.026 3.064.095 4.923.290 2.746.838 3.698.946 3.127.798 4.207.509 
Additional costs 761.957 1.529.690 2.638.948 1.369.600 1.974.463 1.356.548 1.849.551 
Total 4.237.117 7.950.453 13.256.377 7.146.452 9.979.014 7.576.581 10.452.805 
Costs1.000 EUR 2011 2025 2040 2025 2040 2025 2040 
CG 0 1.000.176 2.136.663 3.976.832 1.848.713 2.829.577 1.653.206 1.942.922 
CG 1 780.826 1.587.383 2.735.883 1.452.635 2.152.001 1.486.812 1.966.886 
CG 2 2.456.116 4.226.406 6.543.662 3.845.104 4.997.437 4.436.563 6.542.998 
Cost per PYRS 2011 2025 2040 2025 2040 2025 2040 
Health care 2.412 2.220 2.074 2.279 2.136 2.549 2.804 
Pharmaceuticals 499 475 450 486 464 519 545 
Nursing 2.825 2.512 2.286 2.601 2.392 2.992 3.388 
Production loss 5.819 4.752 4.159 4.864 4.288 6.059 6.374 
Additional costs 2.533 2.373 2.230 2.425 2.289 2.628 2.802 
Total 14.088 12.331 11.200 12.653 11.568 14.676 15.835 
Cost per PYRS        
Comp 0 6.013 5.737 5.616 5.768 5.611 6.106 6.066 
Comp 1 13.600 12.829 12.465 12.932 12.569 13.955 14.101 
Comp 2 31.887 28.450 25.556 29.140 26.711 31.929 32.659 
 
In Figure 2and Figure 3 respective total cost estimates and cost per PYRS for the three contrasting scenarios 
until 2040 are presented. 
The core scenario predicted the Danish Diabetes population to increase to 1,183,630 patients in 2040, nearly 
four times the level in 2011, if current trends in incidence, mortality and complication progression were contin-
ued. This resulted in total diabetes attributable costs of 13.3 billion EUR in 2040 corresponding to 11,200 EUR 
per PYRS. The constant scenario, where all epidemiological indicators were held constant, resulted in the lowest 
prevalence and lowest total costs (660,102 patients and 10.5 billion EUR in 2040), however the highest costs per 
PYRS (15,835 EUR). This reflects that the core scenario assumes continued improvements in treatment results 
and hereby a less morbid, however, larger diabetes population where the constant scenario results in a smaller 
and more disease burdened diabetes population due to higher mortality and morbidity. Intermediate scenario was 
placed in between the two in respect to prevalence with 862,623 patients, but with the lowest total costs (9.98 
billion EUR and more or less the same cost per PYRS as Core 11,568 EUR). Cost per PYRS decrease with time in 
both the core and the intermediate scenario as a result of the larger however less morbid diabetes population 
whereas an increase is seen in the constant scenario. The estimated total cost in 2025 are quite similar in the 
three scenarios ranging from 7.1 over 7.6 to 8.0 billion EUR varying hereby with less than 12% from the lowest 
to highest estimate reflecting the inertia of the future development in the diabetes population due tohistoric 
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Figure 2. Total diabetes attributable costs 2011-2040 for the three epidemiological 
scenarios. 
 
 
Figure 3. Cost per PYRS 2011-2040 for the three epidemiological scenarios. 
 
developments and improvements in mortality and morbidity. Not much can be changed in the period up to 2025, 
while after 2025 the impact of different visions for trends setting from the year 2011 can be seen. For 2040, the 
range was 10.0 and 13.3 billion EUR representing a variation of maximum 33%. 
5.2. Cost Distribution According to Sectors 
Looking at costs in the health care sector, these are projected to be between 1.8 and 2.5 billion EUR in 2040 (1.3 
and 1.4 billion EUR in 2025). This is 1.8-2 times (2025) and 2.5- 3.4 times (2040) the current level in 2011. The 
same patterns are projected for pharmaceutical consumption and nursing services resulting in a demand for 
pharmaceuticals in 2040 of between 360 and 530 million EUR and a demand for nursing services in 2040 of 
between 2.7 and 3.4 billion EUR. 
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5.3. Cost Distribution According to Complication Groups 
Cost distributions within the three complication groups in 2011 and in 2040 across the three epidemiological 
scenarios are depicted in Figure 4. 
The relative distribution of costs between complication groups were more or less similar in the core and the 
intermediate scenario, whereas a greater proportion of costs were spent among patients in CG2 in the constant 
scenario (63% compared to relatively 49% and 50%). This was mainly due to a greater volume of patients in 
CG2 in the constant scenario but also due to a steeper cost gradient from CG0 to CG2 in this scenario of 5.4 
times higher cost in CG2 than CG0 compared to 4.6 and 4.8 times in the core and the intermediate scenario, re-
spectively. In 2011 the 25% of patients with major complications consumed 58% of the total resource use con-
sumed by diabetes patients. The part of resource use consumed by patients with major complications decreases 
in 2040 in both the core and the intermediate scenario to app. 50%, whereas it increases in the constant to the 
mentioned 63%. The share of resources consumed by patients with no complications will respectively be 30% 
and 18% in the core and the constant scenario where CG0 will make up 60%, compared to 49% of patients. 
 
 
 
 
Figure 4. Distribution of diabetes attributable costs by complication group and epidemiological scenario. 
5.4. Economic Potentials 
To illustrate the understanding that future epidemiological development in the diabetes population would require 
some form of investment compared to the level of costs in 2011, we created some cases showing, on one hand, 
the level of economic resources that future investments require and, on the other hand, how economic space are-
freed if certain efficiency improvements are realized. Important conclusions from these analyses were: If in-
vestments in primary care were set to increase with 5% annually (H1), investment in new pharmaceuticals with 
2.5% annually (H2), and investment in secondary prevention with 2.5% (SMBG and Patient education) 
(H3a+H3b), the costs incurred by investments in 2025 will be in the range of 250 million EUR in 2025. In 2040 
thecost (H1, H2, H3a+b) incurred will be 1.1 billion. If patients’ own time (H3c) is included, 300 million EUR 
should be added for 2025 and 1.3 billion EUR for 2040. 
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If productivity increases by 1% per year in primary and secondary health care and nursing sectors0.4 and 1.3 
billion EUR would be freed in 2025 and 2040 respectively (H4a and H4b). If usage of secondary care services 
are reduced by 2.5% annually this will free resources in the range of 400 million EUR in 2025 and 1.2 billion 
EUR in 2040 (H5). For nursing services the corresponding numbers are 500 million and 1.4 billion EUR in 2025 
and 2040 (H6). Reduced productivity loss (H7) among patients in CG0 of 2.5% annually will free resources in 
the range of 280 million EUR in 2025, which is more than the sum of the suggested investments in primary care, 
pharmaceuticals and secondary prevention, when patients’ own time are not taken into account. Results of each 
of the hypotheses are given in thesupplementary material (C+D). 
6. Discussion 
The point of departure for the forecasted scenarios are all centrally available data in Danish national health reg-
isters for all Danish diabetes patients in 2011 providing comprehensive estimates of real world evidenced costs 
attributable to diabetes forecasted according to 14 years of epidemiological data and a categorization of diabetes 
patients in three complication groups. This is a novel approach enabling an intuitive understanding of forecast-
ing results as indicators of where diabetes, in a public health perspective, is heading. This study attempts to 
forecast trends in the future diabetes patient population and, hence, expected costs given the current resource 
consumption and productivity loss among diabetes patients. Model input are of highest possible quality, distin-
guishing the BOX-model from majority of international models based on data from population surveys, and the 
model has been validated showing only nonessential deviations[9] [23] [24]. Our analysis is distinct using so-
cietal attributable costs to diabetes including both resource consumption and productivity loss. Furthermore, we 
take into account the dynamics of diabetes and the expected natural history of disease in relation to development 
of late complications. 
The BOX-model is general and intuitive aiming to guide decision makers as to where this disease is heading 
more than making accurate future projections. Trends from the forecasted scenarios may probably be genera-
lized across countries. They indicate that increasing prevalence of diabetes and, hence, costs of diabetes are dif-
ficult to change within the shorter time span and will approximately double the next 10 years primarily due to 
the already achieved historic improvements in diabetes mortality and morbidity. Hereafter, the span is wider 
depending on the epidemiological trends occurring, however, it is realistic to assume a 2.5 or tripling of the pa-
tient population and, hence costs in 2040. Such estimates correspond well with international projections [20]. On 
the cost side, the predictions concerning health care, pharmaceuticals and nursing services are conditional on 
current rates of utilization and supply, which of course will change over time. From a societal perspective, the 
constant scenario can be viewed as a minimum cost under the assumption that 2011 cost structures and supplies 
are continued. This means that incidence rates are stable and no further progress in the health of diabetes pa-
tients in relation to morbidity or mortality occurs. This is probably unrealistic expectations, however,it sets the 
frame for comparison with the core scenario where the difference in costs (2.8 billion EUR in 2040) reflects the 
amount of extra resources necessary, if prevalence increases continues as observed until 2011. The intersmediate 
scenario compared to the core reflects the general public health expectation that primary prevention will result in 
stable or decreased incidence rates compared to historic trends. If this succeeds, a 25% reduction in costs can be 
expected in 2040 compared to the costs in the core scenario.  
We believe that our estimations present intuitive understandable perspectives valuable for decision makers, 
for instance, for the health care system to be ready to meet this chronic disease challenge of a doubling in re-
source demand already in 2025 under current structures. With estimation of economic potentials to the core 
scenario, we aim to highlight how the scenarios can guide cost effectiveness discussions. For instance, interven-
tions aiming to shift treatment of diabetes patients from secondary care to primary care can be compared to the 
threshold of around 500 million EUR in 2025 freed, if a goal of an annual 2.5% decrease is reached. In compar-
ison, a 5% increased investment in primary care will cost an amount in the range of 45 million EUR in 2025. We 
do not argue for a given causal effect of a specific intervention, but merely point out the economic potentials if 
suggested goals were reached or specific investments were made. 
Another important conclusion is that prevalence is a poor measure of disease control when it comes to chronic 
diseases. Lower cost per patient year might be more desirable than lower prevalence as this means that each pa-
tient is living better with his or her disease contributing to a larger prevalent population. Categorization of pa-
tients according to their complication status in three groups is a novel approach, which allows a more general 
view on the disease, which is easy to interpret and communicate. We have previously shown how health care 
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costs and nursing costs increased markedly when patients with diabetes develop minor or major complications. 
Hence, there is great cost saving potential in preventing development of complications among patients with di-
abetes. This is reflected in the intermediate scenario, where focus is placed on efforts to sustain historic im-
provement in epidemiological indicators into the future, but incidence rates are assumed constant. We further 
project a shift in resource consumption from patients with major complications to patients without complications 
due to the volume of patients living with diabetes without complications in the future. 
It must be stressed that the basic patient population in the scenarios has obtained its size and age composition 
as a consequence of access to diabetes treatment and care during decades prior to year 2001. Therefore, a com-
parison of PYRS experienced under competing scenarios reflects the cumulative effect of access to treatment 
over previous decades. In prolonging of this, it is important to bear in mind that costs are an expression of 
supply and demand meaning that patients’ demand will only increase to the extent that the supply is available. In 
the model, discrete time intervals of one calendar year are used and not continuous time reflecting our wish for a 
simple and intuitive modeling approach. Age at diagnosis, and not running age, was used to reflect that the 
model follows a patient with diabetes from diagnose until death concerning age and gender specific costs and 
morbidity and mortality drivers. Forecasting 25 years ahead in time it is obvious that changes over time, in 
health care queues, waiting lists and treatment offers cannot be accommodated for in the model, as these are 
unknown. It is inevitable that modelers will make different choices and apply different assumptions. The in-
cluded hypotheses can throw light on consequences of different assumptions, however, the model will never be 
a perfect representation of the real world [42]. 
7. Conclusion 
Our projections indicate that within the shorter time span increases in the prevalent population, and therefore the 
associated cost, are difficult to change primarily due to the already achieved historic improvements in diabetes 
mortality and morbidity. These will approximately double societal costs of diabetes the next 10 years,assuming 
current trends in morbidity and mortality are maintained.The resulting diabetes population will incur three times 
the current costs in 2040, although the costs per PYRS are falling during the whole period.A 20% reduction in 
cost per PYRS shows how the distribution of patients with complications are expected to change over time with 
patients living better and, hence, on average become less resource demanding with their disease. Prevalence is, 
therefore, a poor measure of disease control in a public health perspective. With marked increases in diabetes 
prevalence, not only resource demand for health care, nursing and pharmaceuticals will increase but also societal 
productivity loss due to the increasing number of patients in the working age.Despite wide uncertainty around 
projections of the future, they enable us to appreciate better the implications for societies of currently observed 
epidemiological trends. Hereby, projections provide a basis for discussing future resource demand and conse-
quently the necessary investments and structural changes. 
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Supplementary Materials 
Table A.Grouping of diagnoses and interventions used for classifying hospital activities by complication states of relevance 
for diabetes, and with respect to diagnostic specificity for diabetes. 
Diagnosis or procedure Qualifying for complication statea Specificity for diabetesb 
Diabetes in pregnancy, childbirth and the puerperium 0 1 
Diabetes, without indication of chronic complication 0 1 
Hypoglycaemiccoma NOS 0 0 
Screening for diabetic retinopathy 0 1 
Drug treatment or instruction specific for diabetes 0 1 
Acute myocardial infarction 1 0 
Diabetes with complication, not further specified 1 1 
Diabetes with complications in peripheral vascular system 1 1 
Diabetes with eye complication 1 1 
Diabetes with footulcer 1 1 
Diabetes with microangiopathy 1 1 
Diabetes with neurological complication 1 1 
Diabetes with peripheral angiopathy 1 1 
Diabetes with renal complication 1 1 
Diabetic cataract 1 1 
Diabetic polyneuropathy 1 1 
Diabetic retinopathy not otherwise specified 1 1 
Diseases of the lens 1 0 
Polyneuropathy 1 0 
Proliferative diabetic retinopathy 1 1 
Uraemia 1 0 
Simplex diabetic retinopathy 1 1 
Cataract, retinopathy in diabetes 1 1 
Diabetic angiopathy in extremities 1 1 
Diabetic nephropathy, Kimmelstiel-Wilson syndrom 1 1 
Neuropathy, diabetic polyneuritis, diabetes 1 1 
Amputation at or below ankle level 1 0 
Coronary bypass operation 1 0 
Surgery for eye complication 1 0 
Teatment of ulcer of lower limb 1 0 
Diabetes with gangraene 2 1 
Diabetes with multiple complications 2 1 
Diabetic maculopathy 2 1 
Dialysis 2 0 
Diseases of the retina 2 0 
Heart failure 2 0 
Kidney transplantation 2 0 
Renalfailure 2 0 
Stroke 2 0 
Blindness 2 0 
Diabetic gangraene 2 1 
Gangrena of lower limb 2 0 
Intracerebral haemorrhage 2 0 
Amputation above ankle level 2 0 
aValue indicates classification state (0, 1 or 2, respectively). bValues 1 and 0 indicate that item is specific for diabetes and unspecific for diabetes, re-
spectively. 
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Table B.Prevalence, total attributable costs and cost per PYRS 2011, 2025 and 2040 in three epidemiological scenarios. 
Scenarios  CORE CORE INTERMEDIATE INTERMEDIATE CONSTANT CONSTANT 
Main results 2011 2025 2040 2025 2040 2025 2040 
Prevalence 300.769 644.738 1.183.630 564.781 862.623 516.239 660.102 
Comp 0 166.327 372.443 708.091 320.497 504.314 270.745 320.276 
Comp 1 57.415 123.738 219.485 112.333 171.215 106.545 139.486 
Comp 2 77.027 148.557 256.055 131.951 187.094 138.949 200.340 
Incidence 29.451 46.756 62.694 34.289 35.967 34.289 35.967 
Mortality 11.714 16.139 23.443 14.246 17.125 21.080 29.281 
Costs 2011 2025 2040 2025 2040 2025 2040 
Health care 725.464.495 1.431.166.663 2.455.206.345 1.286.964.483 1.842.156.831 1.315.790.252 1.850.934.097 
Pharma 149.953.681 306.038.534 532.748.176 274.264.799 400.288.479 267.676.403 359.781.970 
Nursing 849.715.906 1.619.462.228 2.706.184.561 1.468.784.708 2.063.159.419 1.544.346.999 2.236.535.856 
Prod 1.750.025.792 3.064.095.305 4.923.289.744 2.746.838.024 3.698.946.354 3.127.797.930 4.207.509.369 
Add 761.956.851 1.529.690.283 2.638.947.964 1.369.600.181 1.974.463.293 1.356.548.093 1.849.550.722 
Total 4.237.116.724 7.950.453.013 13.256.376.791 7.146.452.195 9.979.014.377 7.576.581.375 10.452.804.987 
Costs 2011 2025 2040 2025 2040 2025 2040 
Comp 0 1.000.175.623 2.136.663.476 3.976.831.728 1.848.713.102 2.829.576.658 1.653.206.164 1.942.921.596 
Comp 1 780.825.699 1.587.383.184 2.735.883.493 1.452.635.301 2.152.000.515 1.486.812.323 1.966.885.574 
Comp 2 2.456.115.402 4.226.406.354 6.543.661.570 3.845.103.792 4.997.437.204 4.436.562.888 6.542.997.816 
Total 4.237.116.724 7.950.453.013 13.256.376.791 7.146.452.195 9.979.014.377 7.576.581.375 10.452.804.987 
Cost per PYRS 2011 2025 2040 2025 2040 2025 2040 
Health care 2.412 2.220 2.074 2.279 2.136 2.549 2.804 
Pharma 499 475 450 486 464 519 545 
Nursing 2.825 2.512 2.286 2.601 2.392 2.992 3.388 
Prod 5.819 4.752 4.159 4.864 4.288 6.059 6.374 
Add 2.533 2.373 2.230 2.425 2.289 2.628 2.802 
Total 14.088 12.331 11.200 12.653 11.568 14.676 15.835 
Cost per PYRS        
Comp 0 6.013 5.737 5.616 5.768 5.611 6.106 6.066 
Comp 1 13.600 12.829 12.465 12.932 12.569 13.955 14.101 
Comp 2 31.887 28.450 25.556 29.140 26.711 31.929 32.659 
Total 14.088 12.331 11.200 12.653 11.568 14.676 15.835 
CostsComp 0 2011 2025 2040 2025 2040 2025 2040 
Health care 89.858.530 192.519.334 357.882.722 167.209.450 254.934.374 146.323.763 173.757.001 
Pharma 49.838.798 110.062.768 207.478.714 95.344.235 147.955.413 81.928.854 96.563.562 
Nursing 42.624.350 94.604.864 179.036.012 82.877.432 130.048.675 73.656.667 91.717.861 
Prod 570.851.210 1.193.708.678 2.203.162.563 1.030.274.736 1.561.946.494 944.518.912 1.100.545.460 
Add 247.002.735 545.767.832 1.029.271.717 473.007.250 734.691.702 406.777.968 480.337.711 
Total 1.000.175.623 2.136.663.476 3.976.831.728 1.848.713.102 2.829.576.658 1.653.206.164 1.942.921.596 
CostsComp 1        
Health care 140.219.673 302.987.736 535.364.206 276.895.072 420.743.614 265.840.227 352.108.316 
Pharma 41.115.818 87.645.991 152.374.975 80.431.870 120.556.747 78.113.986 104.168.247 
Nursing 132.137.580 279.397.935 486.999.832 256.937.075 387.705.039 251.399.983 339.344.222 
Prod 342.957.246 651.973.536 1.099.551.688 594.900.265 857.994.243 655.209.285 856.531.503 
Add 124.395.382 265.377.986 461.592.792 243.471.020 365.000.871 236.248.842 314.733.286 
Total 780.825.699 1.587.383.184 2.735.883.493 1.452.635.301 2.152.000.515 1.486.812.323 1.966.885.574 
Costs Comp 2        
Health care 495.386.292 935.659.594 1.561.959.417 842.859.962 1.166.478.842 903.626.263 1.325.068.780 
Pharma 58.999.065 108.329.774 172.894.487 98.488.694 131.776.319 107.633.562 159.050.161 
Nursing 674.953.976 1.245.459.429 2.040.148.717 1.128.970.201 1.545.405.705 1.219.290.350 1.805.473.773 
Prod 836.217.336 1.218.413.092 1.620.575.493 1.121.663.023 1.279.005.617 1.528.069.732 2.250.432.405 
Add 390.558.733 718.544.466 1.148.083.456 653.121.912 874.770.720 713.521.284 1.054.479.725 
Total 2.456.115.402 4.226.406.354 6.543.661.570 3.845.103.792 4.997.437.204 4.436.562.888 6.542.997.816 
C. Sortsøet al. 
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Table C.Results of the economic potentials: investments. 
Hypotheses Core Scenario  
Description Continuation of observed epidemiological trends and 2011 cost structure 
 2025 2040 
Total costs €7,934,796,435 €13,230,271,423 
 Core adjusted—H1 
 Investments in primary care (annual +5%) 
 2025 2040 
Total costs €7,979,606,895 €13,459,970,529 
cost difference 2011 Core −€44,810,460 −€229,699,106 
 Core adjusted—H2 
 Investments in pharmaceuticals (annual +2.5%) 
 2025 2040 
Total costs €8,060,933,449 €13,786,645,242 
cost difference 2011 Core −€126,137,015 −€556,373,819 
 Core adjusted—H3a 
 Investments in secondary prevention—SMBG (annual +2.5%) 
 2025 2040 
Total costs €7,986,769,133 €13,466,526,139 
cost difference 2011 Core −€51,972,699 −€236,254,715 
 Core adjusted—H3b 
 Investments in secondary prevention—Patient education (annual +2.5%) 
 2025 2040 
Total costs €7,954,901,428 €13,321,575,284 
cost difference 2011 Core −€20,104,993 −€91,303,861 
 Core adjusted—H3c 
 Investments in secondary prevention—Patients’ own time (annual +2.5%) 
 2025 2040 
Total costs €8,229,416,849 €14,562,020,821 
cost difference 2011 Core −€294,620,415 −€1,331,749,397 
 
Table D.Results of the economic potentials: efficiency improvements. 
Hypotheses Core  
Description Continuation of observed epidemiological trends and 2011 cost structure 
 2025 2040 
Total costs €7,934,796,435 €13,230,271,423 
 Core adjusted—H4a 
 Effiency improvements in health care (annual −1%) 
 2025 2040 
Total costs €7,747,319,738 €12,610,749,158 
cost difference 2011 Core €187,476,697 €619,522,265 
 Core adjusted—H4b 
 Efficiency improvements in nursing (annual −1%) 
 2025 2040 
Total costs €7,722,653,826 €12,547,419,820 
cost difference 2011 Core €212,142,608 €682,851,603 
 Core adjusted—H5 
 Reduced usage of nursing services (annual −2.5%) 
 2025 2040 
Total costs €7,452,435,378 €11,825,506,131 
cost difference 2011 Core €482,361,057 €1,404,765,292 
 Core adjusted—H6 
 Reduced usage of secondary care (annual −2.5%) 
 2025 2040 
Total costs €7,522,166,828 €11,994,126,929 
cost difference 2011 Core €412,629,607 €1,236,144,494 
 Core adjusted—H7 
 Reduced productivity loss among patients in CG0 (annual −2.5%) 
 2025 2040 
Total costs €7,655,644,969 €12,332,342,573 
cost difference 2011 Core €279,151,466 €897,928,850 
 
